Addresses
With increasing emphasis on the earlier detection and management of chronic kidney disease (CKD), estimation of the glomerular filtration rate (GFR) has assumed greater importance. It is accepted that use of serum creatinine concentration alone as a marker of kidney function is inadequate; in particular, it has a poor sensitivity for detecting CKD. International recommendations favour the reporting of creatinine-based estimates of GFR using formulae which also take into account age, gender and other variables that affect the relationship between serum creatinine and GFR: in particular, the four-variable formula derived from the Modification of Diet in Renal Disease study is increasingly being used. We have reviewed the literature supporting the use of this formula compared with the well-established Cockcroft and Gault formula. Overall, evidence supports the use of the 4-v MDRD formula as an improved estimate of GFR in people with moderate/advanced CKD. Neither formula performs well in people with normal and mildly reduced kidney function. However, there remain significant problems with this approach and areas where further research is required. In particular, the widespread adoption of estimated GFR reporting has refocused attention on the limitations of creatinine measurement and highlighted clinical situations in which the formulae are inadequate. Introduction: assessing kidney function using the glomerular filtration rate (GFR)
The functional unit of the kidney is the nephron, composed of a glomerulus and a renal tubule: there are approximately one million nephrons in each kidney. The ¢rst step in urine formation is ¢ltration of plasma water at the glomeruli. A net ¢ltration pressure of about 17 mmHg in the capillary bed of the tuft drives the ¢ltrate through the glomerular membrane. Each nephron produces about 100 mL of ultra¢ltrate per day, which on a whole-body basis equates to approximately 200 L/day of ultra¢ltrate, or 140 mL/min. 1 The rate of ultra¢ltration is known as the GFR and is therefore approximately 140 mL/min in the healthy adult human.
Although the kidney has numerous functions, in particular control of electrolyte and water homeostasis, the initiating step in many of these processes is glomerular ¢ltration. The GFR is widely accepted as the best overall measure of kidney function, enabling a statement of the complex functions of the kidney in a single numerical expression. 2 A decrease in GFR precedes renal failure in all forms of progressive kidney disease, with di¡erent kidney pathologies progressing to endstage renal disease (ESRD) and dialysis dependency at rates varying from weeks to several decades. 3 The symptoms accompanying progressive kidney disease (including anaemia, hyperparathyroidism and cardiovascular disease) relate more closely to GFR than to serum creatinine. Measuring GFR is useful in identifying chronic kidney disease (CKD) in order to (a) target treatment to prevent progression and complications, and (b) monitor progression and predict the point at which renal replacement therapy will be required. It is also used as a guide to the dosage of renally excreted drugs to avoid potential drug toxicity.
Classification of kidney disease
Over the last decade, several strands of research have combined to create pressure for new approaches to the classi¢cation of kidney disease. There is evidence of an 'epidemic'of CKD in Western populations for a number of reasons, including ageing of the population and increased prevalence of diabetes. Late referral of patients with advanced CKD to nephrologists remains common and causes avoidable morbidity and mortality. 4 It is now recognized that CKD is a signi¢cant risk factor for vascular disease. 5 These strands of evidence, combined with the development of a National Service Framework (NSF) for Renal Services in England, have led to increasing interest in reliable clinical systems for early recognition and appropriate preventive management of patients with early CKD, paralleling similar initiatives internationally.
A staging system has recently been proposed for CKD in the hope that, as has been observed in other clinical conditions, most notably cancers, it will facilitate improved diagnosis and management of kidney disease ( Table 1 ). This classi¢cation system, proposed by the National Kidney Foundation--Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI), 2 is based predominantly on GFR, although in the earlier stages of CKD other clinical evidence (e.g. presence of proteinuria) is also important. Originally proposed in North America, this system has been accepted, with minor modi¢cation, by the NSF for Renal Services, part 2 6 and by the Kidney Disease: Improving Global Outcomes (KDIGO). 7 Critics have argued that the classi¢cation of kidney disease should also include the underlying cause and strati¢cation according to severity of proteinuria, analogous to the 'tumour, node, metastasis' (TNM) classi¢cation for cancer. 8 The term 'stage'also implies progression, which is misleading, as progression is not inevitable --patients with stage 3 CKD are far more likely to die from cardiovascular disease than they are to progress to stage 4 or 5 CKD. However, the basic principle of classi¢cation according to a formula-based estimate of GFR is now widely accepted in research and clinical practice.
How is GFR measured?
The GFR is a measure of the e⁄ciency of which substances are cleared from the blood by glomerular ¢ltration, and is de¢ned as 'the volume of plasma from which a given substance is completely cleared by glomerular ¢ltration per unit time'. It is measured by quantitating the clearance of an exogenous or endogenous substance by the kidneys. Provided that the substance (S) is in stable concentration in the plasma, is physiologically inert, freely ¢ltered at the glomerulus, and neither secreted, reabsorbed, synthesized, nor metabolized by the kidney, the amount of that substance ¢ltered at the glomerulus is equal to the amount excreted in the urine (i.e. the amount of S entering the kidney must exactly equal the amount leaving it). The amount of S ¢ltered at the glomerulus equals GFR multiplied by plasma S concentration: GFR Â PS. The amount of S excreted equals the urine S concentration (US) multiplied by the urinary £ow rate (V, volume excreted per unit time).
Since ¢ltered S ¼ excreted S
where GFR ¼ clearance in units of mL of plasma cleared of a substance per minute; US ¼ urinary concentration of the substance; V ¼ volumetric £ow rate of urine in mL per minute; and PS ¼ plasma concentration of the substance. The term (US Â V)/PS is de¢ned as the clearance of substance S and is an accurate estimate of GFR, provided the aforementioned criteria are satis¢ed.
A variety of exogenous (radioisotopic and nonradioisotopic) and endogenous markers have been used to estimate clearance. Of these, the fructose polymer inulin (molecular mass approximately 5000 Da) best satis-¢es the above criteria and has long been regarded as the most accurate (gold standard) estimate of GFR (although it should be noted that even inulin has some extra-renal clearance; equivalent to nearly 6 mL/min for a 70 kg human). Assessment of inulin clearance may be done using either a constant infusion urinary clearance approach or a single bolus plasma clearance approach. 9 However, lack of availability of simple laboratory methods of measurement remains an impediment to universal usage and, in practice, a variety of alternative 'silver' standard estimates of GFR are used, including 125 I-iothalamate, 51 Cr-ethylenediaminetetraacetic acid (EDTA), 99m Tcdiethylenetriaminepentaacetic acid (DTPA) and iohexol. These techniques all have relative advantages and disadvantages which are beyond the scope of the discussion here. Of note, 51 Cr-EDTA is preferred to 99m Tc-DTPA and 125 I-iothalamate since its clearance is considered to be closest to that of inulin 10, 11 and the British Nuclear Medicine Society has recently endorsed its use as the standard measure of GFR. 12 Recently, iohexol clearance techniques have been applied to capillary blood/¢lter paper collection systems, which is an attractive alternative to radioisotopic assessments. 13, 14 Although the clearance of infused markers is generally considered an accurate assessment of GFR, the techniques are too labour-intensive and costly for routine clinical use, particularly where there is a need to assess the GFR on a regular basis (e.g. where patients are receiving nephrotoxic drugs). Endogenous markers obviate the need for injection and require only a single blood sample, simplifying the procedure for the patient, the clinician, and the laboratory. The most widely used endogenous marker of GFR is creatinine, expressed either as its serum a concentration or its renal clearance.
The use of creatinine as a marker of GFR was developed in 1926 by Rehberg, 15 who used exogenously administered creatinine. This led to the work of Popper and Mandel, 16 who in 1937 developed the use of endogenous creatinine clearance (CrCl). a Creatinine measurements are equivalent in serum and plasma.We have used the term 'serum' throughout this paper. Serum creatinine measurement su¡ers from a variety of analytical interferences 17, 18 and signi¢cant problems of standardization. 19 Furthermore, its serum concentration is critically dependent on muscle mass: serum creatinine concentration may remain within the reference range despite marked renal impairment in patients with low muscle mass and vice versa. Age, gender, ethnicity and obesity all a¡ect the relationship between serum creatinine, muscle mass/body weight and GFR. Consequently, the sensitivity of serum creatinine for the detection of CKD is poor. 20, 21 Serum creatinine measurement will fail to identify half of the patients with stage 3 CKD (GFR 30--59 mL/min/ 1.73 m 2 ), and performance is even worse in certain patient groups (e.g. older people 22 ). Using 'Couchoud creatinine cutpoints' (gender but not age-speci¢c creatinine concentrations validated against inulin clearance in middle-aged adults and proposed as 'GFR equivalents' 23 ) results in an underestimate of CKD in older people in general, and older women in particular. 24 CrCl has in the past been seen as more sensitive for detection of renal dysfunction than serum creatinine measurement. However, it requires a timed urine collection, which introduces its own inaccuracies 17, 25, 26 and is inconvenient and unpleasant. In adults, the intra-individual day-to-day coe⁄cient of variation (CV) for repeated measures of CrCl exceeds 25%. 27 Although tubular secretion undermines the theoretical value of creatinine as a marker of GFR, in the context of CrCl, this has to some extent previously been o¡set by the use of non-speci¢c methods to measure serum creatinine, which lead to an overestimation of serum concentration. Nevertheless, CrCl usually equals or exceeds inulin GFR in adults by a factor of 10--40% at clearances above 80 mL/min. As GFR falls, plasma creatinine rises disproportionately and the CrCl can reach nearly twice that of inulin. 28 The limitations of CrCl as a marker of GFR have been discussed previously in the Annals: 29, 30 at best, CrCl can only provide a crude index of GFR and there is a need for a more practical and accurate alternative.
Estimating the GFR using creatinine-based formulae
The mathematical relationship between serum creatinine and GFR can be improved by correcting for the confounding variables that prevent the relationship 33 was the product of a retrospective re-analysis of the MDRD study, a multi-centre, controlled trial of the e¡ects of dietary protein restriction and blood pressure control on the progression of kidney disease. GFR was determined in 1628 predominantly middleaged patients with known kidney disease using 125 I-iothalamate, and expressed per 1.73 m 2 body surface area (BSA). Creatinine was measured in a central laboratory using a kinetic Ja¡e assay on a Beckman Astra CX3 analyser. Stepwise multiple regression modelling on log-transformed data was used to determine the set of variables that best predicted GFR. Several models were developed in 1070 of the 1628 patients and subsequently tested on the remainder. The model which gave the best ¢t with true GFR (R 2 0.912) included urinary urea, but a model including only serum measurements was also developed with little loss of accuracy or precision (R 2 0.903). In this model, serum urea was found to be an independent predictor of GFR, probably re£ecting the di¡ering renal handling of urea and creatinine by the kidney, and also to improve the strength of relationship between creatinine and GFR, possibly by correcting for the e¡ects of catabolism on serum creatinine. In addition to urea, they also observed an unexplained predictive e¡ect of serum albumin concentration on GFR. The model also takes into account the fact that the relationship between serum creatinine and GFR di¡ers between Caucasians and African-Americans. The lack of requirement of knowledge of body weight was a practical advantage compared with the Cockcroft and Gault formula, which also gave poorer accuracy in their hands (R 2 0.842), although the inclusion of a term for ethnicity meant that demographic information was still required to enable laboratories to calculate the GFR. (NB: This should not be taken to imply that the Cockcroft and Gault equation does not require correction for ethnic origin; simply that their original study did not address this point.) 37 The requirement for measurement of albumin and urea in addition to creatinine was clearly a limitation of the 6-v MDRD formula, increasing both analytical costs and the contribution of analytical variation. Recognizing this, these workers subsequently published an abbreviated four-variable (4-v ) version of the formula (equation 5), which does not require these measurements and did not result in appreciable loss of accuracy (R 2 0.892), with 90% of subjects having a GFR estimate within 30% of the measured value. 34 Although this version has only ever been published in abstract form, it has 
Relative merits of the Cockcroft and Gault and MDRD formulae
The Cockcroft and Gault formula has been used for more than a quarter of a century and is embedded in clinical practice (e.g. it is commonly the basis for drugdosage adjustments of renally excreted drugs such as aminoglycoside antibiotics). Conversely, experience with the MDRD formula is relatively recent.We limited our literature search to 1999 onwards to enable us to review the studies in which the Cockcroft and Gault and MDRD formulae have been compared directly against each other in a range of clinical settings. We chose only to include studies in which a reference GFR procedure (inulin or other exogenous clearance marker) had been used. Table 3 describes the characteristics of the 13 studies in which a direct comparison has been undertaken. These studies have been reported both from European countries and from North America, and have addressed the issue across a range of kidney functions, including patients with known CKD 38--45 and subjects with normal kidney function (usually potential living donors). 41,43--46 Two studies have speci¢cally addressed the issue in older people 47, 48 and two in type 1 diabetes mellitus. 49, 50 Most studies have looked at predominantly Caucasian populations, the exception being the study of Lewis et al. 38 A variety of creatinine assays has been used and, critically, few of these have been calibrated against the assay from which the MDRD (or Cockcroft and Gault) formulae were derived. Similarly, several reference GFR procedures have been used, with only three studies having used an inulin procedure. 40, 42, 49 Due to the complex nature of the data, it is not possible to summarize the relative performance of the formulae at all levels of GFR, but Table 4 illustrates the main features of the studies identi¢ed. Both formulae perform better at lower GFRs (stage 3--5 CKD), 43, 45 with the MDRD formula being less biased and more precise and accurate than the Cockcroft and Gault estimate, which tends to overestimate GFR in such patients. 38,43--45 Some studies 47, 48 have found the biases to be reversed in older people, with the Cockcroft and Gault formula apparently underestimating GFR and the MDRD formula overestimating it. However, the large studies of Froissart et al. 44 and Poggio et al. 45 found the MDRD estimate to be less biased and more accurate and precise than the Cockcroft and Gault formula in both younger and older people and at normal and reduced levels of kidney function, with the exception 44 of older women with GFR o60 mL/min/1.73 m 2 .
At higher levels of kidney function, the bias and precision of the MDRD estimate is poorer, tending to underestimate true GFR in most studies. 39, 43, 49, 50 Neither approach is very accurate at GFR levels within the reference range, but the Cockcroft and Gault estimate appears more so than the MDRD estimate in most studies. 39, 43, 45, 50 The bias of the Cockcroft and Gault estimate varies, being lower than true GFR in some studies 39, 43, 50 and higher 45, 46 in others.
The Cockcroft and Gault estimate has been adjusted for BSA in most studies, a factor which must be borne in mind, since this is unlikely to re£ect standard clinical practice. However, Lin et al. 46 found that adjusting for BSA had no e¡ect on the bias or accuracy of the formula.
Correction for calibration di¡erences compared with the laboratory from which the MDRD formula was derived improved the bias of the MDRD estimate substantially in some 41, 43, 50 (but not all) 45 studies. Little di¡erence was reported between the GFR estimates provided by the 6-v and 4-v MDRD formula, 46, 47 and, for the reasons given above, there seems little advantage in using the 6-v MDRD formula.
The only study to provide data to calculate the traditional measures of sensitivity and speci¢city was that of Froissart et al. 44 For detecting stage 3 CKD or worse (true GFR o60 mL/min/1.73 m 2 ), both formulae performed well: the MDRD estimate had 93% and 88% sensitivity and speci¢city compared with 92% and 89% for the Cockcroft and Gault estimate. For stage 4--5 CKD (true GFR o30 mL/min/1.73 m 2 ), the MDRD formula had 87% and 96% sensitivity and speci¢city compared with 78% and 97% for the Cockcroft and Gault formula. For detecting less severe (stage 2) CKD (true GFR o90 mL/min/1.73 m 2 ), both were sensitive but neither was speci¢c; the MDRD estimate less so (67% versus 72%).
The variety of creatinine assays, statistical approaches, reference GFR procedures used and populations studied make interpretation di⁄cult. However, a general conclusion can be drawn that, for the detection of patients with stage 3--5 CKD, the MDRD formula provides a more accurate and clinically acceptable assessment of GFR than the Cockcroft and Gault formula.
Some general hypotheses to explain the performance of the formulae can be proposed. Poorer performance of formulae at low serum creatinine concentrations is partly a simple mathematical result of the inverse curvilinear relationship between GFR and serum creatinine concentration. Owing to this relationship, imprecision in measurements of serum creatinine concentration leads to greater imprecision in the estimated GFR when serum creatinine concentration is low. Both formulae were developed in populations which had sub-optimal kidney function (the MDRD formula in particular). It is therefore not surprising that the accuracy of the formula is greatest at levels of GFR resembling those from the population from which they were derived. The overestimation of GFR by the MDRD formula in older populations may re£ect a relatively lower serum creatinine concentration for a given level of GFR in this population, for example, due to reduced muscle mass or undernutrition, compared with the middle aged population in which the MDRD formula was derived. Both formulae are critically susceptible to creatinine assay calibration e¡ects, and this is discussed further below.
The effect of body size
Within the animal kingdom, GFR is proportional to (M) 0.77 , where M is the body mass; metabolic rate is similarly related to body mass, with an exponent of 0.75. 51 In humans, GFR varies enormously with body size over a range from o10 mL/min in a neonate to 200 mL/min in a large adult. To enable comparisons of GFR between individuals, it has become standard practice to normalize GFR to a measure of body size. In normal humans of di¡erent ages and body sizes, both the basal metabolic rate and the weight of the kidney are proportional to BSA. 52 It is therefore this measure which is generally used to adjust GFR when the aim is to express how close renal excretory function is to normal. In 1916, Dela¢eld and Eugene Du Bois described a formula which enabled the estimation of BSA using power functions of height and weight: 53 BSA 56 : some studies have shown that the relationship between GFR and BSA is poor 57 and other adjustments, for example, to extracellular volume, 58 lean body weight or height, 59 have been proposed. As a general rule, as body size increases so does kidney size; hence GFR increases and serum creatinine concentration remains constant despite increased creatinine production. The appropriateness of applying a correction factor derived in a young population (and 75 years ago) to middle-aged or older populations, and the e¡ect this could have on the relative performance of GFR estimating equations, was rarely considered in recent studies. The mean7 standard deviation (SD) BSA of adults enrolled in the MDRD study, for example, was 1.9170.23 m 2 , possibly re£ecting a general increase in body size and/or prevalence of obesity in the population in general, the middle-aged nature of the MDRD CKD cohort or a high prevalence of obesity-related disease (type 2 diabetes mellitus) in the CKD population. Even among non-diabetic participants in the Third National Health and Nutrition Examination Survey (NHANES III), mean BSA was 1.85 m 2 (mean weight was 75 kg). 24 Mean weight in the Cockcroft and Gault study was 72 kg; BSA was not reported.
The e¡ects of correcting GFR are likely to matter most at the extremes of body size: in obese subjects, correction of inulin GFR for BSA has been shown to result in a signi¢cant (420 mL/min/1.73 m 2 ) underestimation of GFR. 59 Conversely, using the Cockcroft and Gault formula can lead to gross overestimation of GFR in obese individuals, since weight is a numerator in the formula (equation 3) and an assumption is made that each kilogram body weight contributes an equivalent amount of creatinine. To an extent this problem could be circumvented by using ideal, instead of actual, weight. This is a critically important issue given the increasing prevalence of obesity in the population in general, and in particular among those in whom detection of kidney disease may be most important (i.e. patients with type 2 diabetes mellitus and hypertension). There is an urgent need for further validation of GFR-estimating equations in the obese. Some studies found no e¡ect on accuracy of including/excluding obese subjects from their studies, 42, 46, 50 and Froissart et al. 44 showed that the MDRD formula was more accurate than the Cockcroft and Gault formula in all body mass index categories, excepting individuals with an index o18.5 kg/m 2 . A critical question is whether corrected or uncorrected GFR estimates are most predictive of outcomes in CKD patients (e.g. cardiovascular events, progression of kidney disease). A Medline search using the terms 'GFR and outcome' and 'GFR and body surface area' (search dated March 2005) yielded no answers to this question and, as Hsu et al. 56 have pointed out, there is di⁄culty in establishing this evidence since normalizing to BSA may introduce spurious associations if BSA, but not absolute GFR, were associated with the outcome of interest (e.g. BSA is clearly positively associated with obesity, which will have its own relationship with cardiovascular events independent of GFR).
Another major clinical reason for requiring an estimate of GFR is to tailor drug dosages of renally excreted drugs. In this setting, it can be argued that absolute clearance (i.e. mL/min) is more important than a BSAadjusted estimate of GFR, unless the dose of drug to be given is also adjusted for BSA. Otherwise, there is a danger that a patient with a small GFR of, say, 30 mL/ min/1.73 m 2 , and an actual BSA of 1m 2 --whose actual GFR is 17 mL/min --will receive a dose appropriate to a patient with nearly double the ability to clear the drug. For renally excreted drugs with a narrow therapeutic margin, accurate knowledge of both BSA and GFR are needed --in this case necessitating radioisotopic measurement of GFR. It will take some time for dosage recommendations in the British National Formulary and in the'Summary of Product Characteristics'of individual drugs to be reconciled with the classi¢cation of CKD according to normalized GFR.
Effect of ethnic origin
African-Americans have relatively high serum creatinine concentrations compared with GFR-matched Caucasians at any given level of GFR, 38 for reasons that may include greater generation of creatinine per kilogram body weight and lower tubular secretion of creatinine. 56 The MDRD formulae were originally validated in African-Americans, but the Cockcroft and Gault formula was not. Unsurprisingly, the MDRD formula gave a better estimate of GFR in African-Americans than the Cockcroft and Gault formula, which tended to underestimate GFR, 38 although a more recent analysis has suggested that the correction factor for black ethnicity in the MDRD formula is too strong. 45 Underestimation (mean bias À8.6720 mL/min/ 1.73 m 2 ) of GFR by the Cockcroft and Gault formula has also been observed in black Caribbeans dwelling in France. 37 It can probably be assumed that the correction factor of 1.21 used for African-Americans in the MDRD formulae is equally valid for British African-Caribbeans, but there is no evidence to con¢rm this.
There is limited published evidence on the applicability of the MDRD or Cockcroft and Gault formulae to South Asians, Chinese or other ethnic groups. Until such evidence becomes available, it is probably reasonable to assume no correction factor for ethnicity in these latter groups, although, if anything, the correction factor may be less than unity (i.e. use of either the MDRD or Cockcroft and Gault formulae may contribute to under-diagnosis of CKD in South Asians). In support of this, a recent study of Pashtun South Asians showed lower mean creatinine excretion than would be expected in age-and gender-matched white individuals, and an apparent overestimation of GFR using both the Cockcroft and Gault and MDRD equations, although it should be pointed out that the reference method in this study was CrCl. 60 This di¡erence was attributed to lower dietary meat intake and to a lower muscle mass for body weight.
Estimated GFR in diabetes
In 2002, diabetic nephropathy was the cause of established renal failure in 19.8% of newly diagnosed patients, and a signi¢cantly higher proportion of those under 65 years. 61 It is therefore crucial that approaches to GFR estimation are valid in the diabetic population. An important study in this respect is that of Ibrahim et al., 50 who applied the Cockcroft and Gault and MDRD formulae to 1286 individuals with type 1 diabetes (and serum creatinine o106 mmol/L) enrolled in the in£uential Diabetes Control and Complications Trial. 62 In this exacting study (reported iothalamate clearances were the mean of four consecutive studies and a veri¢cation of creatinine assay performance against that of the Cleveland Clinic [MDRD] laboratory was undertaken), both formulae gave imprecise estimates (R 2 only 0.11 and 0.13 for the Cockcroft and Gault and MDRD estimates, respectively, against 125 I-iothalamate GFR), with di¡ering biases and accuracies at di¡erent levels of GFR. The poor precision observed re£ects the fact that most patients had physiological GFRs. Overall, it was concluded that the Cockcroft and Gault estimate (BSA-adjusted) was more accurate than the MDRD formula in patients with GFR in the range 60--120 mL/ min/1.73 m 2 . Vervoort et al. 49 also concluded that the Cockcroft and Gault formula was superior in normoalbuminuric patients with type 1 diabetes (mean GFR 122718 mL/min/1.73 m 2 ). However, their data suggest that this is not a consequence of diabetes per se, but simply re£ects the better performance of the Cockcroft and Gault formula compared with the MDRD formula at higher levels of GFR. There have been no speci¢c validation studies in Type 2 diabetes. Ã Estimated GFR compared to reference procedure. Bias has been expressed in a variety of different formats across the 13 studies. To enable comparison, wherever possible we have expressed bias as the mean difference observed between the estimated and reference GFR procedures, as typically calculated using Bland and Altman analysis. In some studies this is expressed as mean 47, 43 or median 45 percentage bias or median absolute differences, 49 and these figures have been quoted. w Estimated GFR compared with reference procedure. z Precision of the estimate has been expressed in a variety of different formats across the 13 studies. Unless stated otherwise, the data shown are either the percentage absolute differences (PAD, 50th, 75th, 90th centiles) or the range which encompasses 95% of the differences as typically calculated using Bland and Altman analysis (95% range, mL/min/1.73 m 2 
Epidemiological data
The Cockcroft and Gault and MDRD formulae give different estimates of the prevalence of the various stages of CKD. 24, 63 An analysis of data derived from nondiabetic participants in the NHANES III study shows that the MDRD formula generally predicts a much greater prevalence of GFRs consistent with stage 2 CKD, while the Cockcroft and Gault formula produces marked increases in prevalence of CKD stages 3--5 with increased age (Table 5 ). There are also marked di¡erences in the predicted prevalence among African-Americans, re£ecting the lack of a correction for black ethnicity in the Cockcroft and Gault formula ( Table 5 ). The association between GFR and several cardiovascular risk factors in a large Dutch study di¡ered importantly depending on the method used to estimate GFR. 64 Obviously, both formulae cannot be correct: erroneous classi¢cation will have implications for individuals and for health-care planning. These might include unnecessary investigation and/or referral to nephrologists, excessive monitoring and interventions and 'disease labelling' (or false reassurance), with consequences for insurance and employment. 8, 65 For health-care systems, there may be unnecessary costs associated with over-referral, which will have resource consequences for nephrology services.
Recommendations for the UK: comparison with international practice
Internationally, recommendations now generally favour use of the MDRD formula. The NKF originally 2 stated that either the Cockcroft ful¢ls these criteria. The Cockcroft and Gault method has been discouraged (but not outlawed) in these guidelines. 7 The Caring for Australians with Renal Impairment guidelines are likely to state: ' Autoanalyzer manufacturers and clinical laboratories should calibrate serum creatinine assays to adjust for interference by ''non-creatinine chromogens''according to the international standard [sic](isotope dilution mass spectrometry). Where assay non-speci¢city is signi¢cant (e.g. the e¡ect of non-creatinine chromogens on the Ja¡e reaction) the assay standardization should correct for this e¡ect in individuals with otherwise normal serum biochemistry. Clinical laboratories should therefore report an estimate of GFR using a prediction equation in addition to reporting the serum creatinine concentration. Overall, the current evidence suggests that the abbreviated [4-v] MDRD formula is the best available equation for automated laboratory reporting of eGFR' (Professor David Johnson, Kidney Health Australia, personal communication). Clinical practice guidelines produced by a working party of the UK Renal Association, Royal College of Physicians of London, and Royal College of General Practitioners, with representation from many other groups, including the Association for Clinical Biochemistry (The UK CKD Guidelines Group), have recommended that the 4-v MDRD formula should be used, re£ecting 'the advantage that knowledge of patient weight is not required to enable calculation of GFR and hence implementation is likely to be facilitated', and further ensuring 'a uniform national approach across the UK and y [consistency] with North American recommendations'. 66 The NSF for Renal Services (Part two: Chronic Kidney Disease, Acute Renal Failure and End of Life Care), 6 which addresses this issue in England only, has recommended that 'Local health organizations can work with pathology services and networks to develop protocols for measuring kidney function by serum creatinine concentration together with formula-based estimation ofyGFRy, calculated and reported automatically by all clinical biochemistry laboratories' . This is necessary to address the ¢rst quality requirement of the NSF, that 'People at increased risk of developing or having undiagnosed CKD, especially people with diabetes or hypertension are iden-ti¢ed, assessed and their condition managed to preserve their kidney function' . The recommendations of the UK CKD Guidelines Group, which was designed to support and facilitate the NSF but is applicable throughout the UK, are reproduced in Box 1. We endorse these recommendations in this review.
Practical issues to consider when implementing estimated GFR IT requirements and demographic data
Implementation of estimated GFR requires either that information on body weight (Cockcroft and Gault) or racial origin (4-v MDRD) is reliably transmitted to the Laboratories should communicate to their users (possibly using the laboratory report) the following information: (a) that GFR estimates between 60 and 89 mL/min/1.73 m 2 do not indicate CKD unless there is other laboratory/clinical evidence of disease (b) that the estimated GFR should be multiplied by 1.212 for African-Caribbean patients, unless ethnic origin was available to the laboratory and this correction has already been applied. There is no need to collect 24 h urine samples to measure creatinine clearance in primary care. Within a renal network, which may or may not be co-terminus with a pathology network, laboratories should provide comparable creatinine results, ideally by the use of identical methodology. This should be audited by internal quality control procedures across the network and satisfactory performance in a national quality assessment scheme. Renal/pathology networks should agree a common approach to the estimation of GFR.
Ã Until these recommendations are implemented, use of the prediction tables (Appendix 1) will allow estimation of GFR from age, gender, ethnic origin and serum creatinine. These tables give a 'best case estimate' of GFR, using the lowest age and creatinine value in each cell for the calculation. w As an alternative, software systems used in primary care could be amended to include one of these formulae and generate an estimate of GFR upon receipt of a creatinine result. However, unless this formula was used automatically every time a creatinine result was entered into a primary care system, this strategy would be less likely to ensure widespread use of estimated GFR, and would also not be applicable to measurements of serum creatinine in other settings, such as hospital outpatient clinics.
Ann Clin Biochem 2005; 42: 321-345 laboratory with the request for creatinine measurement or for software systems used in primary care to be capable of calculating one of these formulae upon receipt of an electronic serum creatinine result. However, the latter strategy would not be applicable to measurements of serum creatinine in other settings, such as hospital outpatient clinics. Local solutions, taking into account available IT support, should be possible. Alternatively, in the case of the MDRD formula, an assumption of Caucasian ethnicity could be made at the laboratory, provided that the result is interpreted in relation to ethnic origin. In this situation, it is important that laboratories communicate to their users that laboratory-reported estimates of GFR may be 20% lower than the true GFR in African-Caribbeans. In the UK such an approach is probably reasonable, at least in areas of high Caucasian ethnicity. Some di⁄culties have been encountered in enabling laboratory information systems to compute the power calculations required for the MDRD formula (e.g. search of the Association for Clinical Biochemistry's discussion list using the search term 'calculated GFR' at: www. jiscmail.ac.uk/archives/acb-clin-chem-gen.html, dated 30 November 2004) . This experience has also been reported using other systems in the USA. 67 Software companies may not perceive modi¢cation of their systems to facilitate this as a priority, but we believe that these problems are ultimately surmountable.
Measurement of serum creatinine
Signi¢cant methodological problems related to the analysis of serum creatinine remain, in particular signi¢cant inter-laboratory di¡erences. 19,68--70 These problems include both bias and imprecision and, in both cases, have their greatest impact in the near-reference range. 69 Between-laboratory variation (CV) across the UK is currently approximately 5% at a concentration of120 mmol/L (UK National External Quality Assurance Scheme (UKNEQAS), distribution 738, January 2005), and there is signi¢cant bias between method groups. The majority of the between-laboratory di¡erence is due to calibration di¡erences. 19, 70 Creatinine is routinely measured using a variety of analytical approaches, including endpoint and kinetic Ja¡e and enzymatic assays. Bias between di¡erent creatinine assays produces predictable and signi¢cant di¡erences in estimates of GFR. 71 There is no universally accepted standardization for creatinine assays and, of relevance here, the relationship of an individual laboratory's assay to that provided by the MDRD (Cleveland Clinic) laboratory is generally unknown. The assay used in the MDRD laboratory produces results 20.3 mmol/L (0.23 mg/dL) lower than those produced by the White Sands Laboratory, which served the NHANES III study. The prevalence data (Table 1) reported from the NHANES III study were derived after adjustment (calibration) of the assay to mimic that of the MDRD laboratory. In the absence of this adjustment, prevalence data for CKD are dramatically di¡erent --for example, the prevalence of stage 3 CKD in non-diabetic adults rises from 3.2% to 12.5%. 72 Furthermore, some manufacturers are now realigning the calibration of their assays to account for reaction of Ja¡e-based methods with non-creatinine chromogens, including protein, ascorbic acid, ketones and glucose. For example, Roche Diagnostics Ltd. (Lewes, Sussex, UK) have realigned their assays on the Cobas Integra and Hitachi systems (used by nearly one-third of UK laboratories) by À18 and À28 mmol/L, respectively. These so-called 'compensated' assays produce lower results at concentrations within the reference range (although a concomitant reassignment of the standard results in higher results at pathological concentrations, with the point of equivalence being approximately 185 mmol/L). 73 These assays produce results more closely aligned to HPLC or isotope dilution mass spectrometry (ID-MS) reference procedures, but they make an assumption that the non-creatinine chromogen interference is a constant between samples, which is clearly an oversimpli¢cation. Predictably, compensation produces signi¢cant increases in estimated GFR among patients with normal kidney function. 41, 45 For example, in our hands, the compensated and uncompensated assays were related by the equation compensated creatinine ¼1.09(uncompensated creatinine)À17 mmol/L. For a 50-year-old white man with an uncompensated creatinine of 80 mmol/L, the 4-v MDRD formula predicts a GFR of 94 mL/min/1.73 m 2 . Using the compensated assay, the creatinine concentration would be 70 mmol/L and the estimated GFR 110 mL/min/1.73 m 2 .
An ideal solution would be an internationally agreed standard, the use of assays speci¢c for serum creatinine, and the development of newer formulae using these assays. Such a scenario is unlikely in the foreseeable future. Although we are aware of international attempts at standardization, it is likely that these will take several years to materialize and, even then, problems of di¡erential reaction from non-creatinine chromogens may persist. Alternative approaches, for example using ID-MS methods, may be feasible in the longer term. A shorter-term solution which has been recommended 69 and adopted by at least one major laboratory provider in the USA 67 would be for laboratories to align their creatinine assay to that used by the MDRD laboratory (or, alternatively, to apply correction factors to the MDRD formula suitable for their own creatinine assays). A parallel situation, the alignment of glycosylated form of haemoglobin (HbA 1c ) methods to the assay used in the Diabetes Control and Complications Trial, 62 is generally considered to have facilitated improved and consistent approaches to the care of patients with diabetes --until the development of an international reference method 74 that revealed that the 'harmonized' method on which common clinical practice guidelines are now based gave results too high by around 2%. This has led to concern that adoption of the reference method will cause widespread confusion and (possibly) clinical harm until clinicians and patients learn to re-calibrate diabetes management to the new, lower HbA 1c measurements. 75 This experience is likely to temper enthusiasm within the laboratory community for harmonization of creatinine assays unless they are based on a true 'gold standard'. 76 Within a renal network, which may or may not be co-terminus with a pathology network, laboratories should endeavour to provide comparable creatinine results, ideally by the use of identical methodology. Commutability should be audited by internal quality control procedures within the network and satisfactory performance in a national external quality assessment scheme. Further, a common approach to the estimation of GFR should be agreed within the network.
Estimated GFR formulae have been most extensively evaluated in patients with some degree of renal impairment. Several studies 43--45,50 have shown signi¢cant underestimation of GFR using the 4-v MDRD formula in patients with higher levels of kidney function (Table 4 ). Furthermore, the impact of bias discussed above and, additionally, the imprecision of creatinine assays have their greatest e¡ect on estimated GFR when creatinine is within the reference range. Given this, and the fact that identi¢cation of stage 3 CKD probably has greater clinical implications than stage 2, it has been proposed by the NKDEP that estimated GFR reporting should be limited to values below 60 mL/min/1.73 m 2 (www. nkdep.nih.gov/resources/laboratory_reporting.htm, accessed 1 July 2005). Whether patients whose estimated GFR is 60--89 mL/min/1.73 m 2 but who have no other evidence of CKD should be considered as having CKD simply because of a moderate reduction in GFR is controversial. This question is discussed at length in the NKF-K/DOQI guidelines. 2 There is a danger of 'labelling' many people who feel completely well as having CKD. 8, 72 However, in particular high-risk groups, there is some evidence that reduced GFR, irrespective of other evidence of CKD, is associated with poorer prognosis compared with completely normal kidney function. 5,77--79 Furthermore, estimated GFRs between 60 and 89 mL/min/ 1.73 m 2 are only consistent with CKD in the presence of other laboratory/clinical evidence of renal disease (e.g. microalbuminuria, proteinuria). The UK CKD Guidelines Group has recommended that when estimated GFR exceeds 89 mL/min/1.73 m 2 , it should be reported as X90 mL/min/1.73 m 2 . 66 At GFR levels in the reference range neither estimate is accurate: when accurate GFR information is required we would recommend that reference methods should be used. For potential living kidney donors, use of a radioisotopic estimate of GFR, preferably combined with gamma-camera imaging to assess di¡erential kidney function, is recommended by the British Transplantation Society. 80 
Education
Health professionals familiar with the interpretation of serum creatinine results may require education to appreciate the signi¢cance of GFR (and the concept of estimated GFR). Implementation of estimated GFR should occur in parallel with local education programmes, supported by electronic linked alerts to guidance on the signi¢cance of the results and management of the patients. The Renal Information Exchange Group in the UK (www.renal.org/rixg/, accessed 1 July 2005) is producing such a web-based decision support system, allowing patients registered with a renal unit to see their own results (www.renalpatientview.org/, accessed 1 July 2005) with links to further information depending on GFR estimates. At a minimum, laboratories should communicate to their users (possibly using the laboratory report) the following information:
(1) Which formula has been used in the estimation;
(2) That GFR estimates between 60 and 89 mL/min/ 1.73 m 2 should not be considered as evidence of kidney disease unless there is other, pre-existing laboratory or clinical evidence of disease; (3) That, unless information on ethnic origin was available to the laboratory and taken into account, reported GFR estimates should be adjusted upwards by approximately 20% in African-Caribbeans.
Acute renal failure
Laboratory users should be warned that --just as for measurements of serum creatinine concentration -estimates of GFR are unreliable in acute renal failure, due to the kinetics of creatinine accumulation. 81 
Limitations
There are several clinical situations in which precise knowledge of GFR is important, and where reliance on formula-based estimates of GFR should be avoided. These include cancer chemotherapy, or the use of any other drug that is renally excreted and has a narrow therapeutic margin; the assessment of potential living related kidney donors; and the assessment of GFR in patients with muscle wasting disorders, including spina bi¢da and paraplegia.
Further questions/areas of research
It is clear that the current approach to classi¢cation of CKD is a major improvement on the use of serum creatinine concentrations alone. However, the adoption of formula-based estimates of GFR has focused attention on the limitations of creatinine as a ¢ltration marker, on the limitations of currently used assays for serum creatinine, and on the variation in creatinine production rates in di¡erent disease states and in di¡erent ethnic groups. There is a pressing need for further research to answer questions in several key areas.
Assessment of GFR close to the reference range
The MDRD formula was validated in patients with known CKD, but performs less well in patients with near-normal kidney function and in those with high GFRs (for instance, those with hyper¢ltration due to diabetes). Even if a perfect formula relating creatinine concentration to GFR could be developed, however, there is still the problem that inaccuracies in measurement of serum creatinine concentration have proportionally larger e¡ects on the estimated GFR when serum creatinine concentration is at the lower end of the reference range than when it is abnormal --due to the reciprocal relationship between GFR and serum creatinine. Similar problems will beset the use of any other endogenous ¢ltration marker. Solutions to these problems require both improvements in the precision of the assay used to measure serum creatinine and further work to validate creatinine-based estimates of GFR to 'gold standard' methods, or an approach to measurement of GFR around the reference range that does not depend on endogenous ¢ltration markers at all (e.g. iohexol clearance).
Standardization, or harmonization, of assays for serum creatinine concentration
Clinically important di¡erences in estimated GFR within an individual may arise, dependent solely upon which laboratory is measuring the creatinine. If there is widespread adoption of ID-MS creatinine methods, it will be necessary to re-calibrate formula-based estimates of GFR using these methods against 'gold' or 'silver'standard GFR procedures.
Normalization of GFR to BSA
This has become a convention, and the use of normalization appears likely to be further reinforced by the widespread use of the MDRD formula, which avoids the requirement for input of the patient's body weight because it predicts a normalized GFR. However, further research must address the question of whether complications of kidney disease are better predicted by normalized or actual GFR and, if the former, which BSA correction should be used? Further, how does correc-tion for BSA in£uence epidemiological data on the prevalence of CKD when di¡erent racial groups are being compared, and is correction appropriate in the obese population?
What is the best endogenous filtration marker?
In particular, does the use of cystatin C (which is relatively unin£uenced by age, gender and body weight) either directly or as a component of a GFR-estimating formula, 82, 83 o¡er signi¢cant advantages either because there is less inter-assay variation, or because of better prediction of GFR when close to the reference range? Further, would its introduction be cost-e¡ective?
Which is the best way to estimate GFR from serum creatinine?
For instance, computerized 'evolving connectionist systems' which use adaptive modelling may o¡er advantages over simple formulae. 84 
Ethnic minorities
Validation of creatinine-based GFR estimates in di¡erent ethnic groups, particularly South Asians and Chinese --although the need for such adjustments also serves to highlight the inadequacies of the use of creatinine as an endogenous ¢ltration marker, and will not solve the numerous problems caused by using selfreported ethnic origin in an increasingly heterogeneous population.
Monitoring kidney function over time
Assessment of changes in kidney function over time in an individual patient may be done either by plotting the reciprocal of serum creatinine over time, or by plotting GFR over time. Both are susceptible to the same problems of interpretation, since the only variable that is changing over time is the serum creatinine concentration. Studies on intra-individual variation in serum creatinine over time suggest that a change of around 14% in serum creatinine concentration can be taken as meaningful, but similar studies have not to our knowledge been repeated at extremes of kidney function. 85--87 Among patients with supranormal GFR, assessments based on serum creatinine are inaccurate when compared with iothalamate clearance; changes in cystatin C were more accurate. 88 Among patients with CKD, assessment of the rate of change of GFR can reliably be performed using creatinine-based formulae. 38 
Clinical outcomes
Ultimately, the most important test of a policy to report GFR estimates must relate directly to clinical outcomes; will adoption of this policy, along with the necessary decision support, lead to better outcomes among patients with CKD, and does one formula o¡er advantages over the other in this respect? There have been no randomized controlled trials of outcome in a population comparing the use of serum creatinine alone with reporting of estimated GFR. Markers of better outcome could include the rate of late referral for renal replacement therapy (which might be expected to fall due to better recognition of CKD), quality of life, and life expectancy among patients with CKD (which should increase due to better management of risk factors both for cardiovascular disease and for progressive fall in GFR). Intermediate process measures could include rates of treatment for hypertension, anaemia, hyperphosphataemia and proteinuria. (The inclusion of quality of life measures would be particularly desirable, to address the question of whether 'labelling' individuals as having CKD is harmful.) 8
Conclusions
Estimated GFR is a crude index of kidney function, susceptible to a variety of confounding factors. However, despite these major limitations, the use of estimates of GFR will improve the recognition, 31 and probably the subsequent management, of patients with CKD, compared with use of serum creatinine alone. Most studies have suggested that, in terms of accuracy and bias, there are slight advantages to using the MDRD formula, as opposed to the Cockcroft and Gault formula, in patients with moderate CKD (stage 3) or worse. Both formulae demonstrate deteriorating performance as GFR increases; however, it must be remembered that a diagnosis of CKD stage 2 is not based upon GFR alone, but requires other supporting evidence of kidney disease, most notably proteinuria or microalbuminuria. Neither formula adequately estimates GFR in patients with physiological range GFRs, an important consideration when monitoring patients with diabetes or assessing the suitability of potential kidney donors. In our opinion, the 4-v MDRD formula is more likely to gain widespread acceptance, since knowledge of patient weight is not required to enable calculation of GFR and hence implementation is likely to be facilitated. Further validation of the 4-v MDRD formula in a variety of clinical settings and at varying levels of kidney function is still required. In the longer term, we anticipate that improved formulae based upon reference creatinine methodology, or alternative approaches to GFR measurement, will supplant the use of the MDRD formula. 55 51  48  46  44  43  42  160  51  47  44  42  41  40  39  170  48  44  41  40  38  37  36  180  45  41  39  37  36  35  34  190  42  39  36  35  34  32  32  200  39  36  34  33  32  31  30  210  37  34  32  31  30  29  28  220  35  33  31  29  28  27  27  230  34  31  29  28  27  26  25  240  32  29  28  27  26  25  24  250  31  28  27  25  24  24  23  260  29  27  25  24  23  23  22  270  28  26  24  23  22  22  21  280  27  25  23  22  21  21  20  290  26  24  22  21  21  20  19  300  25  23  21  21  20  19  19  310  24  22  21  20  19  18  18  320  23  21  20  19  18  18  17  330  22  20  19  18  18  17  17  340  21  20  19  18  17  17  16  350  21  19  18  17  17  16  16  360  20  18  17  17  16  16  15  370  19  18  17  16  16  15  15  380  19  17  16  16  15  15  14  390  18  17  16  15  15  14  14  400  18  16  15  15  14  14  13  410  17  16  15  14  14  13  13  420  17  15  15  14  13  13  13  430  16  15  14  14  13  13  12  440  16  15  14  13  13  12  12  450  15  14  13  13  12  12  12  460  15  14  13  13  12  12  11  470  15  14  13  12  12  11  11  480  14  13  12  12  11  11  11  490  14  13  12  12  11  11  11  500  14  13  12  11  11  11  10  41  40  130  48  44  42  40  39  37  36  140  44  41  38  37  35  34  33  150  41  38  35  34  33  32  31  160  38  35  33  31  30  29  29  170  35  33  31  29  28  27  27  180  33  30  29  27  26  26  25  190  31  29  27 
